Featuring: publicly traded & venture capital companies on the U.S. (NYSE, NASDAQ, AMEX & OTC: BB) and Canadian (TSX & TSX-V) stock exchanges, Investment & Money Management Ideas. |
|
Press Release - Vical Incorporated (VICL-NASDAQ) |
|
|
We can apply our technology for vaccines; we can apply it for proteins, animal health applications, cancer. We are focusing on vaccines because vaccines are now probably the single most important medical advance that is going to be required in the next fifty years to deal with a variety of diseases as well as a variety of cancers. We are focused on one of the most lucrative applications of this technology. - Vijay B. Samant (VICL) (Interview published February 15, 2007) |
The Most Powerful Name In Corporate News and Information. |
|
CURRENT ISSUE | COVER ARCHIVES | INDEX | CONTACT | FINANCIALS | SERVICES | HOME PAGE |
|
Vical to Present at Canaccord Genuity Growth Conference
SAN DIEGO, Aug. 4, 2010 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today announced that the company's President and Chief Executive Officer, Vijay B. Samant, will provide an overview of the company's technologies and development programs at the Canaccord Genuity 30th Annual Growth Conference (Boston, August 10 – 12). A webcast of Mr. Samant's presentation at the conference will be available live (4:30 p.m. EDT on Wednesday, August 11) and archived through the Events page in the Investors section of the Vical website at www.vical.com. About Vical Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Potential applications of the company's DNA delivery technology include DNA vaccines for infectious diseases or cancer, in which the expressed protein is an immunogen; cancer immunotherapeutics, in which the expressed protein is an immune system stimulant; and cardiovascular therapies, in which the expressed protein is an angiogenic growth factor. The company is developing certain infectious disease vaccines and cancer therapeutics internally. In addition, the company collaborates with major pharmaceutical companies and biotechnology companies that give it access to complementary technologies or greater resources. These strategic partnerships provide the company with mutually beneficial opportunities to expand its product pipeline and address significant unmet medical needs. Additional information on Vical is available at www.vical.com. The Vical Incorporated logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=5768 CONTACT: Vical Incorporated Alan R. Engbring (858) 646-1127 www.vical.com
|
ceocfointerviews.com does not purchase or
make
recommendation on stocks based on the interviews published.